Skip to main content
Premium Trial:

Request an Annual Quote

Illumina to Market, Sell Neogen GeneSeek Arrays for Genotyping Livestock

NEW YORK (GenomeWeb) – Neogen of Lansing, Michigan, said today that Illumina will market and sell microarrays developed by Neogen's GeneSeek genomics laboratory for the agrigenomics market.

Under the agreement, customers will be able to purchase GeneSeek Genomic Profiler SNP arrays from Illumina, initially for genotyping cattle, pigs, and horses. The arrays, which use Illumina's Infinium BeadArray technology, are available in high- and low-density versions.

Lincoln, Nebraska-based GeneSeek, which Neogen acquired five years ago, provides SNP genotyping and next-gen sequencing services for a number of animal and plant species and is one of Illumina's largest agrigenomics customers.

The agreement, terms of which are undisclosed, is an extension of an existing 2008 strategic relationship between the companies and "will provide other laboratories an ability to run the same highly researched chips we use in our lab," said Neogen Vice President of Corporate Development Jason Lilly in a statement.

Lilly said he expects customers of the arrays to be primarily international genotyping service labs that are unable to ship samples to its Nebraska or Scotland facilities but still want to use Neogen's arrays.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.